Prometheus Biosciences, Inc., (RXDX) News
Filter RXDX News Items
RXDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RXDX News Highlights
- RXDX's 30 day story count now stands at 3.
- Over the past 8 days, the trend for RXDX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- TOP and TG are the most mentioned tickers in articles about RXDX.
Latest RXDX News From Around the Web
Below are the latest news stories about PROMETHEUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RXDX as an investment opportunity.
Top Healthcare Stocks for June 2023Top healthcare stocks include Theravance Biopharma for best value, Dr Reddy's Laboratories for fastest growth, and Viking Therapeutics for most momentum. |
Top Small-Cap Stocks for June 2023Biggest movers include Prometheus, TG Therapeutics, and Akero Therapeutics, all more than quadrupling in price in the last year while the Russell 2000 Index stays nearly unchanged. |
3 Innovative Growth Stocks to Buy for Next-Gen ProfitsThese are the innovative growth stocks for future profits and these stocks are poised for multibagger returns. |
Is Bristol Myers Squibb a Top Dividend Stock?Its hefty yield isn't the only reason to consider buying this top pharma stock. |
3 Undervalued Pharma Stocks to Buy for High Total ReturnsThese are the undervalued pharma stocks to buy for high total returns as these companies are poised for steady growth and cash flow upside. |
What Makes Prometheus Biosciences (RXDX) an Attractive Investment Choice?Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The first quarter was difficult for the fund, as it failed to participate in the broader market rally and declined 3.69% compared to the 3.27% decline for the benchmark Russell […] |
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?Does Prometheus Biosciences, Inc. (RXDX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
Top Small-Cap Stocks for May 2023Biggest movers include Prometheus, Arcellx, and Madrigal, all more than quadrupling in price in the last year while the Russell 2000 Index is nearly unchanged. |
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue EstimatesPrometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 74.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress- Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 -SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 1 |